NOVAVAX INC Selling, General and Administrative Expense
NOVAVAX INC (NVAX) reported Selling, General and Administrative Expense of $26.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- NOVAVAX INC selling, general and administrative expense for the quarter ending 2026-06-30 was $26.66M, a 38.86% decline year-over-year.
- NOVAVAX INC selling, general and administrative expense for the quarter ending 2026-03-31 was $28.78M, a 40.16% decline year-over-year.
- NOVAVAX INC selling, general and administrative expense for the quarter ending 2025-12-31 was $34.12M, a 56.44% decline year-over-year.
- NOVAVAX INC selling, general and administrative expense for the quarter ending 2025-09-30 was $31.66M, a 55.26% decline year-over-year.
- NOVAVAX INC selling, general and administrative expense for fiscal 2025 was $157.48M, a 53.30% decline from fiscal 2024.
- NOVAVAX INC selling, general and administrative expense for fiscal 2024 was $337.19M, a 28.10% decline from fiscal 2023.
- NOVAVAX INC selling, general and administrative expense for fiscal 2023 was $468.95M, a 4.04% decline from fiscal 2022.
- NOVAVAX INC selling, general and administrative expense for fiscal 2022 was $488.69M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.66M 10-Q · filed 2026-08-06 | $55.44M 10-Q · filed 2026-08-06 | $89.56M derived: sum of 3 quarters · filed 2026-08-06 | $121.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $28.78M 10-Q · filed 2026-05-06 | $62.90M derived: sum of 2 quarters · filed 2026-05-06 | $94.55M derived: sum of 3 quarters · filed 2026-05-06 | $138.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $65.78M derived: sum of 2 quarters · filed 2026-02-26 | $109.39M derived: sum of 3 quarters · filed 2026-08-06 | $157.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.66M 10-Q · filed 2025-11-06 | $75.27M derived: sum of 2 quarters · filed 2026-08-06 | $123.36M 10-Q · filed 2025-11-06 | $201.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $43.61M 10-Q · filed 2026-08-06 | $91.70M 10-Q · filed 2026-08-06 | $170.04M derived: sum of 3 quarters · filed 2026-08-06 | $240.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $48.09M 10-Q · filed 2026-05-06 | $126.43M derived: sum of 2 quarters · filed 2026-05-06 | $197.18M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $78.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $149.09M derived: sum of 2 quarters · filed 2026-02-26 | $337.19M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $70.75M 10-Q · filed 2025-11-06 | $258.84M 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $468.95M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $488.69M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |